These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21212755)

  • 1. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
    Arendt BM; Allard JP
    Am J Gastroenterol; 2011 Jan; 106(1):78-80. PubMed ID: 21212755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
    Foster T; Budoff MJ; Saab S; Ahmadi N; Gordon C; Guerci AD
    Am J Gastroenterol; 2011 Jan; 106(1):71-7. PubMed ID: 20842109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
    Arad Y; Spadaro LA; Roth M; Newstein D; Guerci AD
    J Am Coll Cardiol; 2005 Jul; 46(1):166-72. PubMed ID: 15992652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and antioxidant vitamins: should co-administration be avoided?
    Tousoulis D; Antoniades C; Stefanadis C
    J Am Coll Cardiol; 2006 Mar; 47(6):1237; author reply 1237-8. PubMed ID: 16545666
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
    Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
    Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
    J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study.
    Sanchez-Peña P; Nouet A; Clarençon F; Colonne C; Jean B; Le Jean L; Fonfrede M; Aout M; Vicaut E; Puybasset L
    Crit Care Med; 2012 Feb; 40(2):594-602. PubMed ID: 21926584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
    Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of atorvastatin in long-term treatment of patients with ischemic heart disease].
    Belousov IuB; Leonova MV
    Kardiologiia; 2003; 43(4):14-7. PubMed ID: 12968598
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought.
    Adams LA; Lindor KD
    Indian J Gastroenterol; 2004; 23(4):127-8. PubMed ID: 15333965
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
    Martín-Castillo A; Castells MT; Adánez G; Polo MT; Pérez BG; Ayala I
    Biomed Pharmacother; 2010 Apr; 64(4):275-81. PubMed ID: 19932590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
    Uzun M; Yiğiner O; Kirilmaz A
    Turk Kardiyol Dern Ars; 2009 Jul; 37(5):364; author reply 365. PubMed ID: 19875919
    [No Abstract]   [Full Text] [Related]  

  • 14. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
    Koh KK; Quon MJ; Han SH; Lee Y; Park JB; Kim SJ; Koh Y; Shin EK
    Int J Cardiol; 2011 Feb; 146(3):319-25. PubMed ID: 19651449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
    Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
    Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    J Am Coll Cardiol; 2009 Jul; 54(4):293-302. PubMed ID: 19608026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
    Tousoulis D; Antoniades C; Vassiliadou C; Toutouza M; Pitsavos C; Tentolouris C; Trikas A; Stefanadis C
    Eur J Heart Fail; 2005 Dec; 7(7):1126-32. PubMed ID: 16051518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
    J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.
    Sdringola S; Gould KL; Zamarka LG; McLain R; Garner J
    Am Heart J; 2008 Feb; 155(2):245-53. PubMed ID: 18215593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.